Pharmacology and Mechanism of Action of Venetoclax

Mechanism of Action

Venetoclax is a BH3-mimetic that specifically blocks the anti-apoptotic B-cell lymphoma-2 (BCL-2) protein, resulting in programmed cell death of malignant cells 1

Venetoclax is metabolized primarily through the CYP3A4/5 enzyme pathway, making drug interactions with CYP3A inhibitors clinically significant 1
When co-administered with strong CYP3A inhibitors, venetoclax exposure increases significantly, requiring dose adjustments 2
Specific dose reductions are recommended when venetoclax is combined with CYP3A inhibitors, such as a 75% dose reduction when combined with posaconazole 1

Venetoclax is approved for newly diagnosed AML in adults ≥75 years or with comorbidities that preclude intensive chemotherapy, in combination with hypomethylating agents or low-dose cytarabine 3
In CLL, venetoclax-based regimens have shown overall response rates of 79.4% in patients with high-risk features such as del(17p) 4
In AML, combination therapy with hypomethylating agents shows 67% complete remission or complete remission with incomplete count recovery 5

Gradual dose ramp-up is essential to mitigate tumor lysis syndrome (TLS) risk, with a starting dose of 20 mg and weekly escalation over 5 weeks to reach the target dose of 400 mg daily in CLL 4, 6
Standard dosing for AML is 400 mg daily in combination with hypomethylating agents 5

Neutropenia is common (40% grade 3-4) and may require growth factor support and/or dose adjustments 4, 1
Thrombocytopenia (15%) and anemia (18%) are also reported 4
Tumor lysis syndrome (TLS) risk is mitigated through gradual dose escalation, prophylaxis, and monitoring 4, 6

For neutropenia, consider dose interruptions to allow for hematologic recovery, and granulocyte colony-stimulating factor may be considered if dose reduction is ineffective 1
For TLS, temporary hold of venetoclax and aggressive management of electrolyte abnormalities, with hospitalization may be required for high-risk patients during dose escalation 6

Strong CYP3A inhibitors significantly increase venetoclax exposure, requiring dose adjustments, such as a 75% dose reduction when combined with posaconazole 1
Alternative antifungals such as echinocandins may be preferred when venetoclax is used 2

The National Comprehensive Cancer Network recommends reducing venetoclax to 100mg daily when using voriconazole as prophylaxis, due to increased venetoclax exposure caused by voriconazole's strong CYP3A4 inhibition 7, 8

The NCCN guidelines state that venetoclax dose must be reduced by 75% when co-administered with strong CYP3A4 inhibitors, such as voriconazole, to minimize the risk of tumor lysis syndrome and severe toxicity 7, 8

The 2025 ECIL guidelines recommend mold-active prophylaxis for AML patients receiving intensive chemotherapy, with a preference for micafungin (B-II recommendation) 9, 10

Micafungin is a preferred alternative to voriconazole, with no CYP3A4 interaction and no required venetoclax dose adjustment, although it has a narrower spectrum of activity 9, 10
Isavuconazole may be considered with caution, as it has lower CYP3A4 inhibition compared to voriconazole, but still requires venetoclax dose adjustment 9, 10

For high-risk patients, the first choice is micafungin, and the second choice is voriconazole 200mg BID with venetoclax reduced to 100mg daily, with monitoring of venetoclax levels if available 7, 8, 9, 10